Exchange: NASDAQ·Updated 07:59 PM EST

ABOS News

News
all
press releases
Acumen Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
Key PointsPhase II ALTITUDE-AD trial top-line results are expected in November 2026...
Nasdaq News: Markets
Acumen Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
Key PointsPhase II ALTITUDE-AD trial top-line results are expected in November 2026...
Nasdaq News: Markets
More News
Acumen Pharmaceuticals (ABOS) Q3 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Acumen Pharmaceuticals Q3 2026 Earnings Call Transcript
Acumen Pharmaceuticals (NASDAQ:ABOS) reported third-quarter financial results on Monday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you byread more...
Benzinga
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.
Zacks
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their sector so far this year.
Zacks
All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy
Acumen Pharmaceuticals (ABOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year?
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their sector so far this year.
Zacks
Acumen Pharmaceuticals (ABOS) Expected to Announce Quarterly Earnings on Tuesday
Acumen Pharmaceuticals (NASDAQ:ABOS) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-acumen-pharmaceuticals-inc-stock...
MarketBeat
Short Interest in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Increases By 46.4%
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) was the recipient of a significant increase in short interest in April. As of April 15th, there was short interest totaling 1,545,029 shares, an increase of 46.4% from the March 31st total of 1,055,415 shares. Approximately 2.4% of the...
MarketBeat
Acumen Pharmaceuticals (NASDAQ:ABOS) Trading 0.7% Higher - Still a Buy?
Acumen Pharmaceuticals (NASDAQ:ABOS) Shares Up 0.7% - Here's Why...
MarketBeat

Advertisement|Remove ads.